-
公开(公告)号：US12036212B2
公开(公告)日：2024-07-16
申请号：US17705798
申请日：2022-03-28
IPC分类号： A61K31/4439 , A61K31/337 , A61K31/404 , A61K31/7048 , A61K31/7068 , A61K45/06 , A61P35/00 , C12Q1/48 , G01N33/574
CPC分类号： A61K31/4439 , A61K31/337 , A61K31/404 , A61K31/7048 , A61K31/7068 , A61K45/06 , A61P35/00 , C12Q1/485 , G01N33/57488 , G01N2800/52 , A61K31/337 , A61K2300/00 , A61K31/7068 , A61K2300/00 , A61K31/7048 , A61K2300/00 , A61K33/24 , A61K2300/00 , A61K31/4439 , A61K2300/00 , A61K31/404 , A61K2300/00
摘要： Disclosed is a method for enhancing tumor response to chemotherapy, the method comprising administering a short-acting anti-angiogenic agent (AAA) capable of activating ASMase to a subject afflicted with a solid tumor, and thereby creating a time interval of increased susceptibility of said tumor to one or more chemotherapeutic agents, followed by administration of at least one chemotherapeutic agent within the interval. The interval can be defined in terms of a short-duration activation of ASMase signaling by the AAA. Disclosed are also methods for predicting the tumor response in a patient afflicted with a solid tumor to a chemotherapeutic agent, using as an indicator of the response ASMase level or activity (or ceramide level) in the patient following the administration of the chemotherapeutic agent to the patient, or dynamic IVIM based DW-MRI to measure perfusion alterations following administration of the chemotherapeutic agent.
-
公开(公告)号：US11285137B2
公开(公告)日：2022-03-29
申请号：US16516235
申请日：2019-07-18
IPC分类号： A61K31/4439 , A61K31/337 , A61K31/7068 , A61P35/00 , A61K31/404 , A61K31/7048 , A61K45/06 , C12Q1/48 , G01N33/574
摘要： Disclosed is a method for enhancing tumor response to chemotherapy, the method comprising administering a short-acting anti-angiogenic agent (AAA) capable of activating ASMase to a subject afflicted with a solid tumor, and thereby creating a time interval of increased susceptibility of said tumor to one or more chemotherapeutic agents, followed by administration of at least one chemotherapeutic agent within the interval. The interval can be defined in terms of a short-duration activation of ASMase signaling by the AAA. Disclosed are also methods for predicting the tumor response in a patient afflicted with a solid tumor to a chemotherapeutic agent, using as an indicator of the response ASMase level or activity (or ceramide level) in the patient following the administration of the chemotherapeutic agent to the patient, or dynamic IVIM based DW-MRI to measure perfusion alterations following administration of the chemotherapeutic agent.
-
公开(公告)号：US20170333413A1
公开(公告)日：2017-11-23
申请号：US15525856
申请日：2015-11-12
IPC分类号： A61K31/4439 , A61K31/7068 , A61K31/337 , C12Q1/48 , G01N33/574
CPC分类号： A61K31/4439 , A61K31/337 , A61K31/404 , A61K31/7048 , A61K31/7068 , A61K33/24 , A61K45/06 , A61P35/00 , C12Q1/485 , G01N33/57488 , G01N2800/52 , A61K2300/00
摘要： Disclosed is a method for enhancing tumor response to chemotherapy, the method comprising administering a short-acting anti-angiogenic agent (AAA) capable of activating ASMase to a subject afflicted with a solid tumor, and thereby creating a time interval of increased susceptibility of said tumor to one or more chemothcrapcutic agents, followed by administration of at least one chemotherapeutic agent within the interval. The interval can be defined in terms of a short-duration activation of ASMase signaling by the AAA. Disclosed are also methods for predicting the tumor response in a patient afflicted with a solid tumor to a chemotherapeutic agent, using as an indicator of the response ASMase level or activity (or ceramide level) in the patient following the administration of the chemotherapeutic agent to the patient, or dynamic IVIM based DW-MRI to measure perfusion alterations following administration of the chemotherapeutic agent.
-
公开(公告)号：US10413533B2
公开(公告)日：2019-09-17
申请号：US15525856
申请日：2015-11-12
IPC分类号： C12Q1/48 , A61K33/24 , A61K45/06 , A61P35/00 , A61K31/337 , A61K31/404 , G01N33/574 , A61K31/4439 , A61K31/7048 , A61K31/7068
摘要： Disclosed is a method for enhancing tumor response to chemotherapy, the method comprising administering a short-acting anti-angiogenic agent (AAA) capable of activating ASMase to a subject afflicted with a solid tumor, and thereby creating a time interval of increased susceptibility of said tumor to one or more chemotherapeutic agents, followed by administration of at least one chemotherapeutic agent within the interval. The interval can be defined in terms of a short-duration activation of ASMase signaling by the AAA. Disclosed are also methods for predicting the tumor response in a patient afflicted with a solid tumor to a chemotherapeutic agent, using as an indicator of the response ASMase level or activity (or ceramide level) in the patient following the administration of the chemotherapeutic agent to the patient, or dynamic IVIM based DW-MRI to measure perfusion alterations following administration of the chemotherapeutic agent.
-
公开(公告)号：US20180015184A1
公开(公告)日：2018-01-18
申请号：US15208335
申请日：2016-07-12
发明人： Richard N. Kolesnick , Branka Stancevic , Michel Sadelain , Zvi Fuks , Nira Varda-Bloom , Dror Harats
CPC分类号： A61K48/0066 , A61K38/46 , A61K48/0058 , C12N2710/10343
摘要： Disclosed herein are methods and compositions for treating cancer by increasing radiation-induced damage to cancer without increasing radiation-induced side effects by increasing secretory ASMase levels specifically in tumor endothelium, and inducing apoptosis of tumor endothelial cells by treating the tumor with radiation. ASMase levels are increased in tumor endothelium by administration of a recombinant DNA construct comprising a region coding for a functional ASMase linked to particular transcriptional regulatory sequences that confer tissue-specific expression of ASMase.
-
6.发明申请METHOD AND COMPOSITION TO INCREASE RADIATION-INDUCED TUMOR THERAPEUTIC EFFECTS 审中-公开增加辐射诱导的肿瘤治疗效果的方法和组合公开(公告)号：US20170007718A1
公开(公告)日：2017-01-12
申请号：US14846513
申请日：2015-09-04
发明人： Richard N. Kolesnick , Branka Stancevic , Michel Sadelain , Zvi Fuks , Nira Varda-Bloom , Dror Harats
CPC分类号： A61K48/005 , A61K35/761 , A61K38/00 , A61K45/06 , A61N2005/1098 , C12N9/16 , C12N15/86 , C12N2710/10332 , C12N2710/10343 , C12N2830/002 , C12N2830/008 , C12N2830/15 , C12N2830/85
摘要： Disclosed herein are methods and compositions for treating cancer by increasing radiation-induced damage to cancer without increasing radiation-induced side effects by increasing secretory ASMase levels specifically in tumor endothelium, and inducing apoptosis of tumor endothelial cells by treating the tumor with radiation. ASMase levels are increased in tumor endothelium by administration of a recombinant DNA construct comprising a region coding for a functional ASMase linked to particular transcriptional regulatory sequences that confer tissue-specific expression of ASMase.
摘要翻译： 本文公开了通过增加辐射诱导的癌症损伤而不增加辐射诱导的副作用的方法和组合物，通过在肿瘤内皮中特异性增加分泌型ASMase水平，并通过用辐射治疗肿瘤来诱导肿瘤内皮细胞的凋亡。 通过施用重组DNA构建体，ASMase水平增加，所述重组DNA构建体包含与赋予ASMase的组织特异性表达的特定转录调控序列连接的功能性ASMase的区域。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.021 秒)
